New radiation boost aims to zap prostate tumors harder, faster
NCT ID NCT07325721
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new radiation approach for men with high-risk or locally advanced prostate cancer. It combines hypofractionated radiotherapy (fewer, larger doses) with a microboost that delivers extra radiation to the most aggressive tumor spots. The goal is to improve cancer control while keeping side effects manageable. About 46 men will receive 25 radiation sessions along with standard hormone therapy, and researchers will track urinary and bowel side effects, PSA levels, and quality of life for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hypofractionated radiation therapy with a focal microboost
What this could lead to
If successful, this approach could offer a more effective and convenient radiation treatment for high-risk prostate cancer, potentially improving tumor control without increasing side effects.
What could go wrong
This is a small, early-phase trial with only 46 participants, so results may not apply to all patients. The higher radiation dose could increase urinary or bowel side effects, and long-term benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of South Carolina Hollings Cancer Center
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••